ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ABUS Arbutus Biopharma Corporation

2.71
0.03 (1.12%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Arbutus Biopharma Corporation NASDAQ:ABUS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.03 1.12% 2.71 2.64 2.79 2.85 2.70 2.71 683,613 01:00:00

Arbutus to Present at UBS Virtual Global Healthcare Conference

12/05/2020 1:00pm

GlobeNewswire Inc.


Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Arbutus Biopharma Charts.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 11:40 AM ET.

A live webcast of the presentation can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast. An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection.  The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. For more information, visit www.arbutusbio.com.

Contact Information

Investors and MediaWilliam H. CollierPresident and CEOPhone: 604-419-3200Email: ir@arbutusbio.com

Pam MurphyInvestor Relations ConsultantPhone: 604-419-3200Email: ir@arbutusbio.com

1 Year Arbutus Biopharma Chart

1 Year Arbutus Biopharma Chart

1 Month Arbutus Biopharma Chart

1 Month Arbutus Biopharma Chart

Your Recent History

Delayed Upgrade Clock